CN1320819A - Phlegm-treating agent for examining cancer cells - Google Patents
Phlegm-treating agent for examining cancer cells Download PDFInfo
- Publication number
- CN1320819A CN1320819A CN 00110366 CN00110366A CN1320819A CN 1320819 A CN1320819 A CN 1320819A CN 00110366 CN00110366 CN 00110366 CN 00110366 A CN00110366 A CN 00110366A CN 1320819 A CN1320819 A CN 1320819A
- Authority
- CN
- China
- Prior art keywords
- phlegm
- treating agent
- cancer cells
- milliliters
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A phlegm-treating agent for detecting cancer cells and clinical cytologic diagnosis contains ammonium cetylbromide, propanediol, alcohol, carbowax and isotonic phosphate solution as buffering liquid, and can be used to dissolve phlegm, prevent fouling and cell deformation, immobilizing cancer cells and preserving cell humidity. Its advantages are simple examine method and high currectness and reliability.
Description
The present invention relates to a kind for the treatment of agent that is used for the sputum sample of examining cancer cells.Be applicable to lung cancer people at highest risk generaI investigation and clinical cytology diagnosis.
The clinical inspection diagnosis and the main method of cytology somatotype to lung cancer is pathological examination to lung cancer, the sample that is used for pathologic finding generally is to get by bronchoscopic forceps, swollen thing puncture of lung and sputum obtain, because of pincers are got and lung is worn and got sample the patient is caused certain painful and damage, so sputum is that the method for sample is more simple and easy to do, is widely used in clinical diagnosis.
Lung carcinoma cell mainly adopts the sputum specimen method of direct smear in the clinical examination sputum at present, because thick sputum, mucus is covered the cell composition, being not easy to smear and microscopy observes, and the cast-off cells in the sputum are dispersed in the mucus, make the cell density in the visual field little, the yielding or destruction of cell, it is low to detect positive rate.
The purpose of this invention is to provide mucus in a kind of dissolving phlegm, be easy to make qualified cell smear, can make that the cell composition fully dissociates out in the phlegm, the cell density in the visual field becomes hundred times of ground to increase, the rate height is examined in inspection, and the phlegm-treating agent that is used for examining cancer cells anticorrosion, bacteriostasis is arranged.
Phlegm-treating agent of the present invention contains dissolving mucus, fixing cancer cell, and the component of antiseptic and inhibiting bacteria function is characterized in that it is made up of following part by weight component:
Cetyl ammonium bromide 0.1-0.8%;
Propylene glycol 1-10%;
Ethanol 20-40%;
And the distilled water of surplus.
For the ease of smear, keep the humidity of cancer cell, add the part by weight component of carbowax 0.05-1.0%.
For preventing sputum cancer cell deformation and failure, add isotonic phosphate buffer liquid in addition, its part by weight component is as follows: sodium chloride 0.1-0.30%; Sodium dihydrogen phosphate 0.65-0.85%;
Dipotassium hydrogen phosphate 0.18-0.20%;
Sodium bicarbonate 0.03-0.05%.
Preparation method: cetyl ammonium bromide, carbowax be dissolved in 10% the distilled water, again isotonic phosphate buffer liquid component be dissolved in 50% the distilled water,, shake up promptly with adding the distilled water of propylene glycol, ethanol and surplus behind two kinds of solution mixings.
Using method: it is in 100 milliliters the collection sputum test tube that 40 milliliters of the phlegm-treating agents prepared are sub-packed in volume, issues the person under inspection, leaves and takes phlegm morning on the three continuously, coughs in the 1-2 mouth phlegm inlet tube censorship after three days every day.The phlegm pipe of censorship is centrifugal 10 minutes with 1000 rev/mins, discard most of supernatant, leave and take a small amount of supernatant, with suction pipe sediment and liquid are stirred evenly, draw one on microslide, be drawn into cell smear with another microslide to pressing pusher, dye microscopy behind the sheet with " hematoxylin-eosin " decoration method.
The present invention is used for the phlegm-treating agent dissolving sample of examining cancer cells after centrifugal, precipitation sampling microscopy, prevented the interference of thick liquid to film-making, make the cell composition fully dissociate out, the cell density in the visual field becomes hundred times of ground to increase, and has improved the detection positive rate.Treating agent of the present invention has anticorrosion, antibacterial effect, helps film-making operator's health.
In clinical examination 1346 examples, make a definite diagnosis lung cancer person's 228 examples, suspicious lung cancer person's 124 examples at the phlegm-treating agent of the Anshan iron and steel plant SHUGUANG HOSPITAL internal application embodiment of the invention 3 preparation.
Patients with lung cancer 228 examples that detect through sputum, be diagnosed as patient's 326 examples of lung cancer through radiotherapy, chemotherapy surgery Pathology, the positive rate that proves sputum examination is 69.9%, and the unprocessed film-making inspection of sputum sample, detect 74 examples in the formerly certified 210 routine patients with lung cancer, positive rate is 35.2%.
Embodiment 1
Cetyl ammonium bromide 4 grams, 315 milliliters of 95% ethanol, 20 milliliters of propylene glycol, 665 milliliters of distilled water.
The preparation method: the cetyl ammonium bromide is dissolved in 100 ml distilled waters, and mixing shakes up promptly behind 565 milliliters of distilled water of adding and ethanol, the propylene glycol.
Embodiment 2
Cetyl ammonium bromide 4 grams, carbowax 1 gram, 315 milliliters of 95% ethanol, 20 milliliters of propylene glycol, 665 milliliters of distilled water.
Preparation method: cetyl ammonium bromide and carbowax are dissolved in 100 ml distilled waters, shake up promptly behind 565 milliliters of distilled water of adding, ethanol, the propylene glycol.
Embodiment 3
Cetyl ammonium bromide 4 grams, carbowax 1 gram, 315 milliliters of 95% ethanol, 20 milliliters of propylene glycol, 665 milliliters of distilled water, sodium chloride 2 grams, sodium dihydrogen phosphate 7.568 grams, dipotassium hydrogen phosphate 1.86 grams, sodium bicarbonate 0.4 gram.
Preparation method: cetyl ammonium bromide 4 grams, carbowax 1 gram are dissolved in 100 ml distilled waters, again with sodium chloride 2 grams, sodium dihydrogen phosphate 7.568 grams, dipotassium hydrogen phosphate 1.86 grams, sodium bicarbonate 0.4 gram is dissolved in 500 ml distilled waters, with above-mentioned two liquid mixings, shake up promptly after adding 65 milliliters of 315 milliliters of 95% ethanol, 20 milliliters of propylene glycol and distilled water.
Claims (3)
1. phlegm-treating agent that is used for examining cancer cells is characterized in that it is made up of following part by weight component:
Cetyl ammonium bromide 0.1-0.8%;
Propylene glycol 1-10%;
Ethanol 20-40%;
And the distilled water of surplus.
2. phlegm-treating agent according to claim 1 is characterized in that wherein adding the part by weight component of carbowax 0.05-1.0%.
3. phlegm-treating agent according to claim 1 and 2 is characterized in that wherein adding isotonic phosphate buffer liquid, and its part by weight component is as follows:
Sodium chloride 0.1-0.30%;
Sodium dihydrogen phosphate 0.65-0.85%;
Dipotassium hydrogen phosphate 0.18-0.20%;
Sodium bicarbonate 0.03-0.05%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00110366 CN1111282C (en) | 2000-04-26 | 2000-04-26 | Phlegm-treating agent for examining cancer cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00110366 CN1111282C (en) | 2000-04-26 | 2000-04-26 | Phlegm-treating agent for examining cancer cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1320819A true CN1320819A (en) | 2001-11-07 |
| CN1111282C CN1111282C (en) | 2003-06-11 |
Family
ID=4580360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00110366 Expired - Fee Related CN1111282C (en) | 2000-04-26 | 2000-04-26 | Phlegm-treating agent for examining cancer cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1111282C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101988875A (en) * | 2010-09-03 | 2011-03-23 | 江苏省原子医学研究所 | Sputum liquid-based treating fluid |
| CN103471892A (en) * | 2013-09-22 | 2013-12-25 | 厦门大学附属第一医院 | Method for preparing pulled type cervical smear |
| CN103884549A (en) * | 2014-02-11 | 2014-06-25 | 中国人民解放军北京军区总医院 | Sputum cell treatment liquid and application thereof |
| CN111238893A (en) * | 2020-01-19 | 2020-06-05 | 湖北泰康医疗设备有限公司 | Method for extracting humoral cells for detecting lung cancer |
-
2000
- 2000-04-26 CN CN 00110366 patent/CN1111282C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101988875A (en) * | 2010-09-03 | 2011-03-23 | 江苏省原子医学研究所 | Sputum liquid-based treating fluid |
| CN103471892A (en) * | 2013-09-22 | 2013-12-25 | 厦门大学附属第一医院 | Method for preparing pulled type cervical smear |
| CN103884549A (en) * | 2014-02-11 | 2014-06-25 | 中国人民解放军北京军区总医院 | Sputum cell treatment liquid and application thereof |
| CN111238893A (en) * | 2020-01-19 | 2020-06-05 | 湖北泰康医疗设备有限公司 | Method for extracting humoral cells for detecting lung cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1111282C (en) | 2003-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aisner et al. | Torulopsis glabrata infections in patients with cancer: increasing incidence and relationship to colonization | |
| Naylor et al. | Chronic obstructive pulmonary disease: usefulness of clinical signs, bronchoalveolar lavage, and lung biopsy as diagnostic and prognostic aids | |
| Maartens et al. | The clinical presentation and diagnosis of invasive fungal infections | |
| CN1111282C (en) | Phlegm-treating agent for examining cancer cells | |
| Salari et al. | Prevalence of Ureaplasma urealyticum and Mycoplasma genitalium in men with non-gonococcal urethritis | |
| Nakamura et al. | Staphylococcus aureus and repeat bacteremia in febrile patients as early signs of sternal wound infection after cardiac surgery | |
| Armstrong et al. | Effects of bile, infection and pressure on pancreatic duct integrity | |
| Roggli et al. | Comparison of sputum and lung asbestos body counts in former asbestos workers | |
| Sgrelli et al. | Achromobacter denitrificans renal abscess | |
| Olson et al. | Not everything acid fast is Mycobacterium tuberculosis--a case report. | |
| US4351823A (en) | Diagnosis of tumors or bacterial infections having β-glucuronidase activity | |
| Imwidthaya | Mycotic keratitis in Thailand | |
| Washizawa et al. | Ultrastructural alteration of glomerular anionic sites in nephrotic patients | |
| CN102512463B (en) | Extraction method of nettle extract | |
| CN112741080B (en) | Liquid-based cell preservation treatment liquid and preparation method and application thereof | |
| CN104306364A (en) | Use of rheum officinale monomer in preparation of medicines for inhibiting Streptococcus suis or intervening Streptococcus suis biofilm | |
| Randhawa et al. | Survey of Cryptococcus neoformans in the respiratory tract of patients with bronchopulmonary disorders and in the air | |
| CN113244267A (en) | Red algae polysaccharide nano-silver, antibacterial gel prepared from red algae polysaccharide nano-silver and application of antibacterial gel | |
| CN113244268A (en) | Bacteriostatic gel containing sulfated polysaccharide-nano silver complex and application thereof | |
| Özen et al. | DMSA renal scanning versus urography for detecting renal scars in vesicoureteral reflux | |
| Sohn et al. | The Effect of Chemotherapy on Tuberculous Pleurisy: A Serial Study of 191 Needle Biopsy Specimens in 41 Patients | |
| CN114403130B (en) | Liquid-based cell preservation solution and preparation method and application thereof | |
| Ishida et al. | Five cases of mucormycosis in paranasal sinuses | |
| Judson et al. | Recent micturition does not affect the detection of urethral gonorrhoea. | |
| Rostami et al. | A rare case of empyema necessitatis sustained by Nocardia farcinica in a kidney transplant recipient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |